ArticleiScience2025
Single-molecule imaging quantifies oncogenic KRAS dynamics for enhanced accuracy of therapeutic efficacy assessment.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Highly branched complex-type N-glycans on integrin β1 in extracellular vesicles enhance the binding of sEVs to laminin on recipient cells.The Journal of biological chemistry · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncogenic KRAS mutations are frequent in colorectal cancer, presenting substantial challenges due to constitutive activation and resistance to molecular-targeted therapies driven by mutation-specific biochemical properties. In this study, using single-molecule imaging, we quantitatively analyzed diffusional behaviors of oncogenic KRAS mutants and associated signaling molecules to elucidate their signaling mechanisms and therapeutic implications. Upon EGF stimulation, KRAS molecules exhibited transient trapping and reduced diffusion due to interactions with SOS1 and BRAF, leading to the temporary formation of signaling complexes. Our results demonstrate that analysis of the temporal fraction and frequency of transient trapping events offers a more sensitive and precise evaluation of KRAS activation levels than western blotting. Furthermore, the study of dynamics of individual oncogenic KRAS molecules provides a more accurate assessment of the therapeutic efficacy of various molecular-targeted drugs. Consequently, we propose a highly sensitive strategy to enhance the therapeutic targeting of oncogenic KRAS in living colorectal cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.